CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Oct. 02, 2016	Dec. 31, 2015
Assets
Cash and cash equivalents	[1],[2]	$ 2,094	$ 3,641
Short-term investments	[1]	12,277	19,649
Trade accounts receivable, less allowance for doubtful accounts: 2016—$672; 2015—$384	[1]	9,836	8,176
Inventories	[1],[3]	7,507	7,513
Current tax assets	[1]	2,825	2,662
Other current assets	[1]	2,843	2,154
Assets held for sale	[1]	1,119	9
Total current assets	[1]	38,501	43,804
Long-term investments	[1]	9,507	15,999
Property, plant and equipment, less accumulated depreciation: 2016—$14,838; 2015—$13,502	[1]	13,284	13,766
Identifiable intangible assets, less accumulated amortization	[1],[4]	54,238	40,356
Goodwill	[1]	56,281	48,242
Noncurrent deferred tax assets and other noncurrent tax assets	[1]	1,859	1,794
Other noncurrent assets	[1]	4,759	3,420
Total assets	[1]	178,430	167,381
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt	[1]	13,633	10,159
Trade accounts payable	[1]	3,476	3,620
Dividends payable	[1]	1,821	1,852
Income taxes payable	[1]	1,158	418
Accrued compensation and related items	[1]	2,048	2,359
Other current liabilities	[1]	12,623	10,990
Total current liabilities	[1]	34,759	29,399
Long-term debt	[1]	30,437	28,740
Pension benefit obligations, net	[1]	5,312	6,310
Postretirement benefit obligations, net	[1]	1,808	1,809
Noncurrent deferred tax liabilities	[1]	31,687	26,877
Other taxes payable	[1]	4,767	3,992
Other noncurrent liabilities	[1]	6,059	5,257
Total liabilities	[1]	114,829	102,384
Commitments and Contingencies	[1]
Preferred stock	[1]	25	26
Common stock	[1]	461	459
Additional paid-in capital	[1]	82,534	81,016
Treasury stock	[1]	(84,346)	(79,252)
Retained earnings	[1]	72,846	71,993
Accumulated other comprehensive loss	[1]	(8,214)	(9,522)
Total Pfizer Inc. shareholders’ equity	[1]	63,306	64,720
Equity attributable to noncontrolling interests	[1]	294	278
Total equity	[1]	63,601	64,998
Total liabilities and equity	[1]	$ 178,430	$ 167,381

[1] Amounts may not add due to rounding.

[2] Amounts may not add due to rounding.

[3] The change from December 31, 2015 reflects, among other things, the reclassification of $369 million to Assets held for sale during the third quarter of 2016 (see Note 2B).

[4] The increase in Identifiable intangible assets, less accumulated amortization, is primarily related to assets acquired as part of the acquisitions of Medivation, Anacor and Bamboo (see Note 2A), the impact of foreign exchange and the impact of measurement period adjustments related to our acquisition of Hospira (see Note 2A), partially offset by amortization, impairments and the reclassification of $1.3 billion to Assets held for sale during the third quarter of 2016 (see Note 2B). For information about impairments, see Note 4.